ACC1 selective inhibitor
/ Takeda
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Design, synthesis and pharmacological evaluation of ACC1 selective inhibitors for cancer treatment
(AACR 2026)
- "Among them, oxazole compound exhibited more potent in vivo efficacy than ureido compound in several xenograft mice models. This finding was the first example to show anti-tumor efficacy by the treatment with ACC1 specific inhibitor as a single agent."
Oncology • ACACA
1 to 1
Of
1
Go to page
1